Glycopyrrolate · Glyrx-Pf, Lonhala Magnair Kit

What is Glycopyrrolate?

Glycopyrrolate is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors, reducing salivary, gastric, and airway secretions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Glyrx-Pf, Lonhala Magnair Kit

Drug type

Small molecule

Targets

muscarinic acetylcholine receptor

Mechanism

Antagonist of muscarinic acetylcholine receptor

Pathways

acetylcholine signaling

Therapy area

Dermatology

Developer

Casper Pharma Llc

In trials of

DERM

FDA status

Approved as Glyrx-Pf, Lonhala Magnair Kit (August 11, 1961), NDA012827 · FDA label

✅ FDA-approved uses

• Peptic ulcer symptoms (Glycopyrrolate)
• Reduction of salivary, tracheobronchial, and pharyngeal secretions during anesthesia (Glyrx-Pf)
• Reduction of gastric secretions during anesthesia (Glyrx-Pf)
• Blockade of cardiac inhibitory reflexes during anesthesia and intubation (Glyrx-Pf)
• Counteraction of arrhythmias intraoperatively (Glyrx-Pf)
• Protection against peripheral muscarinic effects of cholinergic agents (Glyrx-Pf)

From the indications section of the FDA label (version of Feb 17, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hyperhidrosis

Sources

• FDA label (DailyMed)
• FDA label Glycopyrrolate (2026-02-17), indications
• FDA label Glyrx-Pf (2025-07-23), indications
• ClinicalTrials.gov NCT02129660
• ClinicalTrials.gov NCT02129660

Updated Oct 3, 2026.